Vertex cystic fibrosis drug succeeds in combo trial

April 18 Thu Apr 18, 2013 4:44pm EDT

April 18 (Reuters) - Vertex Pharmaceuticals Inc said its experimental drug improved lung function in adults with cystic fibrosis in a mid-stage trial, sending its shares up sharply in after-hours trading.

The company said on Thursday the favorable results were seen in patients who took its experimental drug VX-661 in combination with the company's already approved treatment for cystic fibrosis, Kalydeco (ivacaftor).

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article